Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2020-03-11 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
独立董事关于对公司聘任2020年度审计机构发表的事前认可意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors providing a prior approval opinion on the appointment of the 2020 audit firm for the company. It references regulatory rules and the company's articles of association, and it is dated March 11, 2020. The content is about the approval of the audit firm appointment, not the audit report itself or the annual report. The document length is very short (396 characters), indicating it is a brief announcement or opinion rather than a full report. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit-related announcements and opinions, excluding full annual reports. FY 2020
2020-03-11 Chinese
《公司章程》修正案
Governance Information Classification · 95% confidence The document is a detailed amendment to the company's Articles of Association (公司章程), specifying changes to various articles related to board members, shareholder meetings, voting procedures, and management roles. It references regulatory guidelines and legal provisions relevant to corporate governance and shareholder rights. The content is focused on governance rules and internal company regulations rather than financial performance, audit results, or shareholder meeting results. It is not a report of financial results, audit, or voting outcomes, nor is it a brief announcement or presentation. The document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2020-03-11 Chinese
2019年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the fiscal year 2019 by 普洛药业股份有限公司 (Pulor Pharmaceutical Co., Ltd.). It contains detailed descriptions of the company's internal control systems, evaluation conclusions, scope of evaluation, and specific control areas such as financing, procurement, asset management, sales, R&D, and financial reporting. The document includes management statements, control defect recognition standards, and rectification status. It is a comprehensive report on internal control evaluation rather than a brief announcement or certification. The length (over 10,000 characters) and detailed content indicate it is a full report. This type of document aligns with an Audit Report / Information (AR) category, which covers standalone audit reports and internal control evaluation results, excluding full annual reports. It is not an Annual Report (10-K) because it does not present full financial statements or company activity overview. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2019
2020-03-11 Chinese
关于对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding an external donation of pharmaceutical products to support COVID-19 pandemic efforts. It includes details about the donation, its value, and the company's statement on the impact of the donation on its business. There is no financial data, no mention of a report being attached or published, no regulatory certification, and no indication of a meeting or voting results. The content is a regulatory announcement about a corporate social responsibility action, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-02-20 Chinese
关于复工情况的进展公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about the progress of resuming work during the COVID-19 pandemic. It contains no financial data, no mention of financial results, no regulatory form references, and no detailed report content. The length is only 501 characters, indicating it is a brief notice. It is not a report itself but an operational update. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-02-13 Chinese
关于公司全资子公司购买的银行理财产品到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 普洛药业股份有限公司 regarding the maturity and redemption of bank wealth management products purchased by its wholly-owned subsidiary. It details specific transactions, amounts, dates, and returns on these financial products. The document is short (1401 characters) and focuses on a specific financial update related to the company's capital usage and investment activities. It does not contain comprehensive financial statements or detailed financial performance analysis typical of annual or interim reports. It is not a report publication announcement since it provides substantive information rather than just announcing a report's availability. The content aligns with updates on company fundraising, financing activities, or capital structure changes, which fits the Capital/Financing Update category (CAP).
2020-01-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.